全文3180字,阅读约需10分钟,帮我划重点划重点01干细胞药物研发企业泽辉生物正式递表港交所,拟主板挂牌上市,中金公司为独家保荐人。02公司核心产品ZH901是中国首个也是唯一一个源自hESC的干细胞来源细胞治疗在研产品,但目前尚未成功“造血”。03由于资金紧张,泽辉生物过往融资所得已有超过9成用于研发和日常运营,账面所剩金额不足亿元。04然而,公司计划兴建新工厂、自建销售团队,因此上市融资...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.